Gilead Sciences Inc
Gilead Sciences Inc (GILD) Straddle
GILD straddle scan found 381 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 49.4%.
Read more
Trading a GILD straddle lets you take a pure volatility position on Gilead Sciences Inc without committing to a direction. Gilead Sciences Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate GILD straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on GILD profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Gilead Sciences Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the GILD straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the GILD straddle is the cleanest expression of that view. Our scanner prices every GILD straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a GILD straddle into a catalyst or short a GILD straddle to harvest decay, the options straddle setups that matter are all in one place.
| Feb 19, 2027 | 210.00 | $60.22 | 154 | 27% | 49.4% | $270.22 | $149.78 | 0 |
| Dec 18, 2026 | 210.00 | $60.30 | 91 | 27% | 49.1% | $270.30 | $149.71 | 0 |
| Jan 15, 2027 | 195.00 | $45.48 | 119 | 27% | 49.0% | $240.48 | $149.52 | 0 |
| Jan 15, 2027 | 200.00 | $50.51 | 119 | 27% | 48.9% | $250.51 | $149.50 | 0 |
| Jan 19, 2029 | 210.00 | $71.85 | 854 | 27% | 48.9% | $281.85 | $138.15 | 0 |
| Mar 19, 2027 | 200.00 | $50.97 | 182 | 27% | 48.8% | $250.97 | $149.04 | 0 |
| Dec 15, 2028 | 230.00 | $86.90 | 819 | 27% | 48.7% | $316.90 | $143.10 | 0 |
| Jun 17, 2027 | 210.00 | $61.52 | 272 | 27% | 48.7% | $271.52 | $148.48 | 0 |
| Dec 15, 2028 | 220.00 | $78.93 | 819 | 27% | 48.7% | $298.93 | $141.08 | 1 |
| Mar 19, 2027 | 210.00 | $60.90 | 182 | 27% | 48.6% | $270.90 | $149.10 | 0 |
As of September 18, 2026
Find the right straddle before volatility moves
Track GILD straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→